Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Aptevo Therapeutics Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +3 vs. Q1 2022
- Shares held
- 795.6K
- −16.3K (−2.0%) vs. Q1 2022
- Total value
- $2.85M
- −$1.92M (−40.2%) vs. Q1 2022
- New holders
- 6
- 6 more added
- Sold out
- 3
- 7 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $224.3K |
| Q1 2026 | 9 | $229.7K |
| Q4 2025 | 11 | $191.4K |
| Q3 2025 | 12 | $717.1K |
| Q2 2025 | 7 | $45.9K |
| Q1 2025 | 8 | $22.8K |
| Q4 2024 | 13 | $208.7K |
| Q3 2024 | 19 | $231.1K |
| Q2 2024 | 18 | $599.1K |
| Q1 2024 | 10 | $12.4K |
| Q4 2023 | 29 | $349.7K |
| Q3 2023 | 26 | $1.13M |
| Q2 2023 | 23 | $1.36M |
| Q1 2023 | 24 | $1.82M |
| Q4 2022 | 27 | $2.27M |
| Q3 2022 | 27 | $2.63M |
| Q2 2022 | 27 | $2.85M |
| Q1 2022 | 24 | $4.76M |
| Q4 2021 | 23 | $5.99M |
| Q3 2021 | 26 | $42.1M |
| Q2 2021 | 29 | $65.5M |
| Q1 2021 | 34 | $89.7M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Aptevo Therapeutics Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 238,844 | $855.0K | 0.00% | −1,975−0.8% | Reduced |
| Schonfeld Strategic Advisors LLC | 146,300 | $524.0K | 0.01% | −1,700−1.1% | Reduced |
| Barclays PLC | 79,001 | $283.0K | 0.00% | +12,200+18.3% | Added |
| Renaissance Technologies LLC | 69,886 | $250.0K | 0.00% | +11,000+18.7% | Added |
| Geode Capital Management, LLC | 52,961 | $189.0K | 0.00% | +234+0.4% | Added |
| BlackRock Inc. | 48,046 | $172.0K | 0.00% | −6,321−11.6% | Reduced |
| Price T Rowe Associates Inc | 46,200 | $165.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 22,272 | $80.0K | 0.00% | −28,824−56.4% | Reduced |
| Bank of New York Mellon Corp | 20,697 | $74.0K | 0.00% | −5,255−20.2% | Reduced |
| Northern Trust Corp | 16,943 | $61.0K | 0.00% | +248+1.5% | Added |
| Veritable, L.P. | 15,722 | $56.0K | 0.00% | +15,722 | New |
| Virtu Financial LLC | 12,768 | $46.0K | 0.00% | +12,768 | New |
| Franklin Resources Inc | 10,788 | $39.0K | 0.00% | −5,112−32.2% | Reduced |
| State Street Corp | 10,941 | $39.0K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 1,559 | $5.00K | 0.00% | +4+0.3% | Added |
| UBS Group AG | 1,107 | $4.00K | 0.00% | +1,107 | New |
| Royal Bank of Canada | 714 | $3.00K | 0.00% | −900−55.8% | Reduced |
| Fifth Third Bancorp | 291 | $1.00K | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 142 | $1.00K | 0.00% | 00.0% | Unchanged |
| FMR LLC | 155 | $1.00K | 0.00% | +155 | New |
| US Bancorp | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 6 | $0 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 40 | $0 | 0.00% | +30+300.0% | Added |
| Earnest Partners LLC | 14 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 30 | $0 | 0.00% | 00.0% | Unchanged |
| Harbour Investments, Inc. | 125 | $0 | 0.00% | +125 | New |
| Truvestments Capital LLC | 95 | $0 | 0.00% | +95 | New |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −19,660−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −204−100.0% | Sold out |
| Money Concepts Capital Corp | 0 | $0 | 0.00% | −7−100.0% | Sold out |